• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Sprint Bioscience

4.45 SEK

-0.89 %

Less than 1K followers

SPRINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.89 %
+25.71 %
+110.90 %
+202.72 %
+207.96 %
+793.57 %
+760.27 %
-36.92 %
-62.09 %

Sprint Bioscience is a research company. The company develops drug candidates that can fight cancer individually or in combination with other drugs. The company has a portfolio of projects that are focused on attacking parts of the processes of cancer cells. The business model is based on a project portfolio and developing projects in parallel in the preclinical phase and then entering into licensing agreements with the global pharmaceutical industry. The company is headquartered in Huddinge.

Read more
Market cap
469.54M SEK
Turnover
806.58K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
28.8.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release04.06.2026 klo 09.00

Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company

Sprint Bioscience
Press release19.05.2026 klo 12.14

Redeye: Sprint Bioscience (Q1 Review): Momentum in the business

Sprint Bioscience
Press release16.04.2026 klo 09.00

Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication

Sprint Bioscience

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release01.04.2026 klo 11.55

Sprint Bioscience appoints Jenni Björnulfson as CFO

Sprint Bioscience
Press release01.04.2026 klo 09.00

Positive results expand the NNMT program into Chronic Kidney Disease

Sprint Bioscience
Press release27.03.2026 klo 11.00

Sprint Bioscience publishes new research findings that strengthen the potential of DCPS inhibitors in AML

Sprint Bioscience
Press release18.03.2026 klo 08.45

Sprint Bioscience presents new preclinical data on DCPS at the AACR Annual Meeting 2026

Sprint Bioscience
Press release17.03.2026 klo 08.45

Sprint Bioscience reports positive results from the VRK1 program

Sprint Bioscience
Press release13.02.2026 klo 14.07

Redeye: Sprint Bioscience (Q4 Review): Promising development

Sprint Bioscience
Press release05.12.2025 klo 09.58

Redeye: Sprint Bioscience (Q3 review) - Gilead deal a strong confirmation

Sprint Bioscience
Press release27.11.2025 klo 15.17

BioStock: Sprint Bioscience: ”We have shown it's possible to make early deals”

Sprint Bioscience
Press release24.11.2025 klo 16.23

BioStock: Sprint Bioscience sells cancer program TREX1 to Gilead

Sprint Bioscience
Regulatory press release24.11.2025 klo 07.08

Sprint Bioscience sells the TREX1 program to Gilead

Sprint Bioscience
Press release19.11.2025 klo 09.17

BioStock: Video from Sprint Bioscience's presentation at BioStock Life Science Summit 2025

Sprint Bioscience
Press release04.09.2025 klo 12.05

Redeye: Sprint Bioscience - A clear objective to secure a new partner

Sprint Bioscience
Press release26.06.2025 klo 17.45

Sprint Bioscience’s DCPS data published in Leukemia

Sprint Bioscience
Regulatory press release18.06.2025 klo 20.18

Sprint Bioscience collaborates to expand its MASH programme into inflammation

Sprint Bioscience
Press release30.05.2025 klo 12.37

Redeye: Sprint Bioscience - Increased pressure ahead of the next sprint baton-exchange

Sprint Bioscience
Press release04.03.2025 klo 11.30

Sprint Bioscience presents the VPS34 program at two scientific conferences

Sprint Bioscience
Press release17.02.2025 klo 11.30

Sprint Bioscience presents preclinical data from the TREX1 program at AACR IO

Sprint Bioscience